Tack Endovascular System®
PURPOSE-BUILT. PRECISION REPAIR. PRESERVES OPTIONS.
Critical limb ischemia (CLI) is the most severe form of peripheral artery disease (PAD) with a high risk of amputation and death. The primary goal of treating CLI is to restore unobstructed blood flow, thus healing wounds, relieving pain and preventing limb loss.

There have been limits in the endovascular technologies available to treat CLI below the knee. Balloon angioplasty is the first line therapy for infrapopliteal interventions but it comes with challenges, including balancing the difficulty of achieving optimal luminal gain with managing dissections—resulting in less than desirable outcomes.

The mechanism of angioplasty inevitably creates arterial dissections. Left untreated, these dissections can lead to acute thrombosis and occlusion of the vessel, causing worsening symptoms and/or repeat procedures. Until now there was no therapeutic intervention option to optimally treat below-the-knee (BTK) dissections with confidence.

7.6 million people suffer from CLI in the US and western Europe\(^1,2\)

50% Left untreated, 50% of patients with CLI will undergo a major amputation or die within the first year\(^3\)

$40-66 billion Revascularization (surgical or endovascular) and amputation costs are $40-66 billion annually\(^4\)
The mechanism of angioplasty inevitably creates arterial dissections.
Optimizing PTA with Precision Dissection Repair

The Tack Endovascular System (4F) is a purpose-built, minimal-metal solution for precision repair of post-PTA dissections. **This novel dissection repair device is the first ever vascular implant FDA approved for below-the-knee therapeutic interventions.**

It is crucial to repair dissections in BTK vessels in order to restore obstructed blood flow, heal wounds, relieve pain, and prevent amputation. The Tack Endovascular System (4F) is the only vascular implant to give physicians the ability to confidently treat challenging post-PTA BTK dissections and improve outcomes for patients with CLI.

An adjunct therapy to balloon angioplasty, Tack optimized PTA repairs BTK dissections with high rates of patency and freedom from CD-TLR, ultimately preserving future treatment options. Pre-loaded with 4 self-expanding and self-sizing nitinol implants, the system can be deployed to treat multiple dissections with a single catheter.

**Tack® Implant**
- 4F /0.014” BTK system
- 150cm working length
- 4 pre-loaded 4F Tack implants
- Self-sizes to tapering vessel diameters from 1.5-4.5mm with a single system
- Accurate (≤1mm) Tack implant deployment
- Nitinol with gold radiopaque markers
No More Device Sizing

Only the Tack Endovascular System features **Adaptive Sizing™** – which allows each Tack implant to adapt to tapering anatomy while maintaining a relatively constant radial force. This means that a single size Tack implant can be used across a wide range of vessel diameters.

**PURPOSE-BUILT:**
The Tack Endovascular System is purpose-built to repair peripheral arterial dissections following balloon angioplasty in ATK and BTK therapeutic interventions.

**PRECISION REPAIR:**
The Tack Endovascular System is a first-of-its-kind solution for focal dissection repair.

**PRESERVES OPTIONS:**
A Tack implant leaves behind significantly less metal than stents, preserving vessel integrity, future treatment options and – ultimately – limbs.
THE STUDY SHOWED THAT THE TACK ENDOVASCULAR SYSTEM:

<table>
<thead>
<tr>
<th>Repairs Dissections</th>
<th>Is Safe</th>
<th>Preserves Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>100.0%</strong> Dissection Resolution</td>
<td><strong>98.7%</strong> 30d Freedom from MALE+POD*</td>
<td><strong>83.1%</strong> 12m K-M Freedom from CD-TLR**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Optimizes PTA</th>
<th>Heals/Improves Wounds</th>
<th>Saves Limbs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>81.3%</strong> 12m K-M Tacked Segment Patency+</td>
<td><strong>84.7%</strong> Wounds Healed or Improved at 12m†</td>
<td><strong>96.1%</strong> 12m K-M Target Limb Salvage in CLI Patients§</td>
</tr>
</tbody>
</table>

TOBA II BTK 12-month results confirm that the Tack Endovascular System (4F, 1.5-4.5mm) is a durable, below-the-knee implant for post-PTA dissection repair that optimizes angioplasty to save limbs.
The TOBA II BTK study is the first to enroll patients with advanced CLI disease and **100% dissected vessels.**

Patients reported **sustained improvement in quality of life at 12 months in EQ-5D-3L scores.**

**Optimize PTA**

The **Tack Endovascular System (4F)** enables confident repair of challenging below-the-knee disease and delivers unprecedented post-PTA results to save limbs. This first-of-its-kind vascular implant is positioned to be the new standard of care for optimized balloon angioplasty, demonstrating improved outcomes in BTK interventions and patients with CLI.

*Images courtesy of Christian Wissgott, MD*
**MALE + POD: composite of all-cause death, above-ankle target limb amputation, or major re-intervention to the target lesion(s), defined as new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis.**

**12 month data has not been reviewed by US FDA.**

* Tacked Segment Patency: 12m DUS flow/no flow in Tacked segment (Tack implant + 5mm artery proximal and distal; Tacks within 1cm are considered same segment); 12 month data has not been reviewed by US FDA.

‡ Includes minor amputation; post-hoc analysis has not been reviewed by US FDA.

§ Target Limb Salvage: freedom from above ankle target limb amputation; Post-hoc analysis, has not been reviewed by US FDA.

REFERENCES


INTENDED USE: The Tack Endovascular System [4F, 1.5-4.5mm] is intended for use in mid/distal popliteal, tibial and peroneal arteries, ranging in diameter from 1.5 mm to 4.5 mm, for the repair of post percutaneous transluminal balloon angioplasty (PTA) dissection(s).

CONTRAINDICATIONS: The Tack Endovascular System is contraindicated for the following:

1. Patients with residual stenosis in the treated segment equal to or greater than 30% after PTA.
2. Tortuous vascular anatomy significant enough to prevent safe introduction and passage of the device.
3. Patients with a known hypersensitivity to nickel-titanium alloy (Nitinol).
4. Patients unable to receive standard medication used for interventional procedures such as anticoagulants, contrast agents and antiplatelet therapy.

Prior to using the Tack Endovascular System, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Tack Endovascular System is CE Mark authorized under EC Directive 93/42/EEC. Adaptive Sizing™ is a trademark of Intact Vascular, Inc. Tack Endovascular System® and Tack® are registered trademarks of Intact Vascular, Inc. Copyright 2020. All rights reserved.

MKT0255 Rev 02 072020